Home » Newsletters » BioWorld Science

BioWorld Science

April 29, 1999

View Archived Issues

Genzyme explores cell therapy for cardiovascular disease

Epitope announces OraQuick agreement with Organon Teknika

Slow-release naltrexone enters the clinic

BioStratum receives patent on antiangiogenic agent

Cypros given notice of allowance on U.S. patent for NCCBs

TMR plus CABG offers positive clinical results

NeXstar: Q1 1999 highlights

Lilly: Q1 1999 highlights

Company Profile: Discovery Laboratories

IGT Pharma initiates phase I testing of antitumor drug

Licensing opportunity from NIH: lavendustin A analogues with antiproliferative activity

Continuing focus on PARP inhibitors at Guilford

Potent, optically pure analogues of camptothecin designed at SCRAS

New CRF antagonists described by DuPont for stress-related disorders

FDA advisory committee does not favor approval of temozolomide for melanoma indication

Sibia identifies novel mGluR5-selective compounds

Purified flaxseed lignan has significant beneficial effects in hypercholesterolemic atherosclerosis

Highly functionalized analogues of ingenol prepared in the search for PKC activators

Triazine-based adenosine antagonists in development at Boehringer Ingelheim

HMR describes new NCBE inhibitor series for cardiovascular disorders

Pyrazoles acting as modulators of cGMP production disclosed by Hoechst Marion Roussel

Merck's Maxalt proves effective in women with menstrual migraine

Open-label trial demonstrates efficacy of gabapentin monotherapy in AIDS-related neuropathy

Aggrenox unanimously recommended for approval for stroke indication

Definitive copromotion agreement for cilostazol signed by Otsuka and Pharmacia & Upjohn

NeuroBloc proves effective and safe in two pivotal trials in cervical dystonia

Botox in migraine, poststroke spasticity: results presented at AAN meeting

Company Profile: Eligix

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Medline raises $6.3B in fourth med-tech IPO of December
BioWorld MedTech
Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Acryl raises $28M IPO, aiming to bridge medical divide with AI
BioWorld MedTech
Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...